A Randomized Prospective Trial Comparing Low-volume Bowel Preparation Methods
Primary Purpose
Colorectal Cancer, Colon Adenoma
Status
Completed
Phase
Phase 3
Locations
Korea, Republic of
Study Type
Interventional
Intervention
PEG-Asc
SPMC 2
Sponsored by
About this trial
This is an interventional supportive care trial for Colorectal Cancer focused on measuring Bowel preparation, Polyethylene glycol with ascorbic acid, Sodium picosulfate with magnesium citrate
Eligibility Criteria
Inclusion Criteria:
- Male or female patients, aged between18 and 80 years undergoing elective outpatient colonoscopy were eligible for the study
Exclusion Criteria:
- patients who had chronic kidney disease, severe heart failure(New York Heart Association [NYHA] class III or IV), uncontrolled hypertension (systolic pressure ≥170 mm Hg, diastolic pressure ≥100 mm Hg), severe constipation, any bowel resection, significant gastroparesis, or suspected bowel obstruction or perforation.
Sites / Locations
- Korea University Anam Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
PEG-Asc
SPMC 2
Arm Description
group 1 (PEG-Asc, N=100) received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
group 2 (SPMC 2, N=100) received one sachet of SPMC at 7 p.m the evening before colonoscopy and another sachet of SPMC at 5 hours before procedure
Outcomes
Primary Outcome Measures
the quality of the bowel preparation using Preparation Scale
Preparation Scale
Secondary Outcome Measures
Completeness of the bowel preparation
Patient compliance was recorded by checking the completeness of the prescribed preparation methods including bowel cleansing agent solution and recommended clear liquid.
the patient's tolerability
Patients were asked with questionnaires about the symptoms associated with the preparation to assess the patients' tolerability before the colonoscopy. Patients were asked whether they experienced any of the following : abdominal fullness, cramping, nausea, vomiting, sleep disturbance, and overall discomfort, and these symptoms were scored on a 5-point scale where 1 = "none", 2 = "mild", 3 = "moderate", 4 = "severe", and 5 = "very severe".
Full Information
NCT ID
NCT02250196
First Posted
September 8, 2014
Last Updated
September 24, 2014
Sponsor
Korea University Anam Hospital
1. Study Identification
Unique Protocol Identification Number
NCT02250196
Brief Title
A Randomized Prospective Trial Comparing Low-volume Bowel Preparation Methods
Official Title
A Randomized, Prospective Tiral on Efficacy and Tolerability of Low-volume Bowel Preparation Methods for Colonoscopy
Study Type
Interventional
2. Study Status
Record Verification Date
September 2014
Overall Recruitment Status
Completed
Study Start Date
March 2013 (undefined)
Primary Completion Date
September 2013 (Actual)
Study Completion Date
November 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Korea University Anam Hospital
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Colonoscopy is a common screening method to detect polyps and CRC. With the early detection of CRC through screening colonoscopy, patients could have better therapeutic effects and outcomes. In population screening programs, an increase in completed colonoscopies is related to a decrease in mortality from CRC. However, the miss rate for detecting colorectal neoplastic polyps of colonoscopy is 5-28%. The reluctance of participants to undergo bowel preparation results in the relatively low rate of detection of polyps and CRC, because poor preparation interferes with successful colon mucosa examination during a colonoscopy.
Low-volume bowel preparations provide equivalent cleansing effect compared with standard 4 liter polyethylene glycol. However, studies comparing the superiority between low-volume bowel preparations are rare, and results are controversial. This study aimed to compare the bowel cleansing quality and tolerability between split-dose sodium picosulfate/magnesium citrate and polyethylene glycol with ascorbic acid.
Detailed Description
Study design: endoscopist-blinded, prospective, randomized controlled trial
Subjects
Entry criteria: Male or female patients, aged between18 and 80 years undergoing elective outpatient colonoscopy were eligible for the study.
Exclusion criteria:
patients who had chronic kidney disease, severe heart failure(New York Heart Association [NYHA] class III or IV), uncontrolled hypertension (systolic pressure ≥170 mm Hg, diastolic pressure ≥100 mm Hg), severe constipation, any bowel resection, significant gastroparesis, or suspected bowel obstruction or perforation.
Sampling design: Consecutive recruitment of consenting patients
Variables Predictor
group 1 (SPMC 2) received one sachet of SPMC at 7 p.m the evening before colonoscopy and another sachet of SPMC at 5 hours before procedure
group 2 (PEG-Asc) received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure;
Primary Outcome: Quality of bowel preparation (Boston Bowel Preparation Scale, Aronchick scale, bubble score)
Secondary Outcome: Tolerability, palatability
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colorectal Cancer, Colon Adenoma
Keywords
Bowel preparation, Polyethylene glycol with ascorbic acid, Sodium picosulfate with magnesium citrate
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Investigator
Allocation
Randomized
Enrollment
200 (Actual)
8. Arms, Groups, and Interventions
Arm Title
PEG-Asc
Arm Type
Active Comparator
Arm Description
group 1 (PEG-Asc, N=100) received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
Arm Title
SPMC 2
Arm Type
Active Comparator
Arm Description
group 2 (SPMC 2, N=100) received one sachet of SPMC at 7 p.m the evening before colonoscopy and another sachet of SPMC at 5 hours before procedure
Intervention Type
Drug
Intervention Name(s)
PEG-Asc
Other Intervention Name(s)
Coolprep®; TaeJoon Pharmaceuticals, Seoul, Korea
Intervention Description
received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
Intervention Type
Drug
Intervention Name(s)
SPMC 2
Other Intervention Name(s)
Picolight(Pharmbio korea, Seoul, Korea)
Intervention Description
received one sachet of SPMC at 7 p.m the evening before colonoscopy and another sachet of SPMC at 5 hours before procedure
Primary Outcome Measure Information:
Title
the quality of the bowel preparation using Preparation Scale
Description
Preparation Scale
Time Frame
20 minutes
Secondary Outcome Measure Information:
Title
Completeness of the bowel preparation
Description
Patient compliance was recorded by checking the completeness of the prescribed preparation methods including bowel cleansing agent solution and recommended clear liquid.
Time Frame
30 minutes before the colonoscopy
Title
the patient's tolerability
Description
Patients were asked with questionnaires about the symptoms associated with the preparation to assess the patients' tolerability before the colonoscopy. Patients were asked whether they experienced any of the following : abdominal fullness, cramping, nausea, vomiting, sleep disturbance, and overall discomfort, and these symptoms were scored on a 5-point scale where 1 = "none", 2 = "mild", 3 = "moderate", 4 = "severe", and 5 = "very severe".
Time Frame
30 minutes before the colonoscopy
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or female patients, aged between18 and 80 years undergoing elective outpatient colonoscopy were eligible for the study
Exclusion Criteria:
patients who had chronic kidney disease, severe heart failure(New York Heart Association [NYHA] class III or IV), uncontrolled hypertension (systolic pressure ≥170 mm Hg, diastolic pressure ≥100 mm Hg), severe constipation, any bowel resection, significant gastroparesis, or suspected bowel obstruction or perforation.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Eun Sun Kim, PhD
Organizational Affiliation
Division of Gastroenterology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
In Kyung Yoo, MD
Organizational Affiliation
Division of Gastroenterology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea
Official's Role
Principal Investigator
Facility Information:
Facility Name
Korea University Anam Hospital
City
Seoul
State/Province
Anamdong 5-ga, Seongbuk-gu
ZIP/Postal Code
136-705
Country
Korea, Republic of
12. IPD Sharing Statement
Learn more about this trial
A Randomized Prospective Trial Comparing Low-volume Bowel Preparation Methods
We'll reach out to this number within 24 hrs